The Indian Journal of Pediatrics

, Volume 79, Issue 5, pp 650–654 | Cite as

RETRACTED ARTICLE: Kearns Sayre Syndrome—Case Report with Review of Literature

  • Meghana Phadke
  • M. R. LokeshwarEmail author
  • Shraddha Bhutada
  • Chandralekha Tampi
  • Renu Saxena
  • Sudha Kohli
  • K. N. Shah
Special Article


Kearns-Sayre Syndrome is form of rare mitochondrial cytopathy, first described by Thomas P. Kearns and George Pomeroy Sayre in 1958 and is characterized by progressive external opthalmoplegia, cardiac conduction block, pigmentary retinal degeneration, variable number of red ragged fibers on muscle biopsy. It presents before the child reaches the age of twenty. Kearns-Sayre syndrome may affect many organ systems and additional features may include myopathy, dystonia, bulbar symptoms in the form of dysarthria and nasal regurgitation and bilateral facial weakness. Endocrine abnormalities (e.g., diabetes, growth retardation/short stature, and hypoparathyroidism), bilateral sensorineural deafness, dementia, cataracts, and proximal renal tubular acidosis, skeletal muscle weakness (proximal more than distal) and exercise intolerance are additional features. Kearns Sayre Syndrome occurs as a result of large-scale single deletions (or rearrangements) of mitochondrial DNA (mtDNA), which is usually not inherited but occurs spontaneously, probably at the germ-cell level or very early in embryonic development. No disease-modifying therapy is available for Kearns-Sayre syndrome (KSS). Management is supportive vigilance for detection of associated problems. In the future, potential treatment in patients with Kearns-Sayre syndrome may attempt to inhibit mutant mtDNA replication or encourage replication of wild-type mtDNA.


Kearns-Sayre’s syndrome CPEO (Chronic progressive external ophthalmoplegia with myopathy) Chronic progressive external ophthalmoplegia with ragged red fibers Oculo cranio somatic neuromuscular disease with ragged red fibers 


Conflict of Interest


Role of Funding Source



  1. 1.
    Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: Unusual syndrome with histologic study in one of two cases. Arch Ophthalmol. 1958;60:280–9.CrossRefGoogle Scholar
  2. 2.
    Jager BV, Fred HL, Butler RB, Carnes WH. Occurrence of retinal pigmentation, ophthalmoplegia, ataxia, deafness and heart block: Report of a case, with findings at autopsy. Am J Med. 1960;29:888.PubMedCrossRefGoogle Scholar
  3. 3.
    Kearns TP. External ophthalmoplegia, pigmentary degeneration of the retina and cardiomyopathy: a newly recognized syndrome. Trans Am Ophthlamol Soc. 1965;63:559–625.Google Scholar
  4. 4.
    Berenberg RA. Lumping or splitting? "Ophthalmoplegia plus" or Kearns-Sayre syndrome? Ann Neurol. 1977;1:37–43.PubMedCrossRefGoogle Scholar
  5. 5.
    Gayathri R, Prasad W, Ramakrishanan R, Prajna NV. Kearns-Sayre syndrome: an atypical presentation. Indian J Ophthalmol. 2000;48:54–5.PubMedGoogle Scholar
  6. 6.
    Mehndiratta MM, Agarwal P, Tatke M, Krishnamurthy M. Neurological mitochondrial cytopathies. Neurol India. 2002;50:162–7.PubMedGoogle Scholar
  7. 7.
    Lee KT, Lai WT, Hwang CH, Yen HW, Voon WC, Sheu SH. Atrioventricular block in Kearns-Sayre syndrome: a case report. Kaohsiung J Med Sci. 2001;17:336–9.PubMedGoogle Scholar
  8. 8.
    DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. Arch Neurol. 1993;50:1197–208.PubMedCrossRefGoogle Scholar
  9. 9.
    Franco E, Bautista J, Kuque R, et al. Mitochondrial encephalomyopathy of late presentation with progressive with progressive ophthalmoplegia, tremor and diffuse leukoencephalopathy. Neurologia. 1999;9:463–6.Google Scholar
  10. 10.
    Berkovic SF, Carpenter SE, Evans A, et al. Myoclonus epilepsy and ragged red fibres (MERRF). Brain. 1989;112:1231–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Harvey JN, Barnett D. Endocrine dysfunction in Kearns-Sayre syndrome. Clin Endocrinol. 1992;37:97–104.CrossRefGoogle Scholar
  12. 12.
    Katsanos KH, Elisaf M, Bairaktari E, Tsianos EV. Severe hypomagnesemia and hypoparathy-roidism in Kearns-Sayre syndrome. Am J Nephrol. 2001;21:150–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Zeviani M, Moraes CT, DiMauro S, et al. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology. 1988;38:1339–46.PubMedGoogle Scholar
  14. 14.
    Lestienne P, Ponsot G. Kearns-Sayre syndrome with muscle mitochondrial DNA deletion. Lancet. 1988;1:885.Google Scholar
  15. 15.
    Fischel-Ghodsian N, Bohlman MC, Prezant TR, Graham Jr JM, Cederbaum SD, Edwards MJ. Deletion in blood mitochondrial DNA in Kearns-Sayre syndrome. Pediatric Res. 1992;31:557–60.CrossRefGoogle Scholar
  16. 16.
    Lertrit P, Imsumran A, Karnkirawattana P, et al. A unique 3.5-kb deletion of the mitochondrial genome in Thai patients with Kearns-Sayre syndrome. Hum Genet. 1999;105:127–31.PubMedCrossRefGoogle Scholar
  17. 17.
    Seneca S, Verhelst H, De Meirleir L, et al. A new mithocondrial point mutation in the transfer RNA (Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch Neurol. 2001;58:1113–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Carod-Artal FJ, Lopez Gallardo E, Solano A, Dahmani Y, Herrero MD, Montoya J. Mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurologia. 2006;21:357–64.PubMedGoogle Scholar
  19. 19.
    Chu BC, Terae S, Takahashi C, et al. MRI of the brain in the Kearns Sayre syndrome: report of four cases and a review. Neuroradiology. 1999;41:759–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Ogasahara S, Yorifuji S, Nishikawa Y, et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q (10) in Kearns-Sayre syndrome. Neurology. 1985;35:372–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Barragan-Campos HM, Barrer-Ramirez CF, Iturralde Torres P, et al. Kearns-Sayre syndrome an absolute indication for prophylactic implantation definite pacemaker? Arch Inst Cardiol Mex. 1999;69:559–65.PubMedGoogle Scholar
  22. 22.
    Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia device. Circulation. 2002;106:2145.PubMedCrossRefGoogle Scholar
  23. 23.
    Usui M, Takagi Y, Masumoto H, Ueda U. Pacemaker therapy in Kearns-Sayre syndrome. Kyoubu Geka. 2002;55:1112–4.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2011

Authors and Affiliations

  • Meghana Phadke
    • 1
  • M. R. Lokeshwar
    • 1
    • 4
    Email author
  • Shraddha Bhutada
    • 1
  • Chandralekha Tampi
    • 3
  • Renu Saxena
    • 2
  • Sudha Kohli
    • 2
  • K. N. Shah
    • 1
  1. 1.Department of PediatricsLilavati Hospital and Research CenterMumbaiIndia
  2. 2.Center of Medical GeneticsSir Gangaram HospitalNew DelhiIndia
  3. 3.Department of PathologyLilavati Hospital and Research CenterMumbaiIndia
  4. 4.MumbaiIndia

Personalised recommendations